Catalyst Pharmaceuticals Inc (CPRX)
15.12
+0.40
(+2.68%)
USD |
NASDAQ |
Apr 24, 16:00
15.12
0.00 (0.00%)
After-Hours: 18:18
Catalyst Pharmaceuticals Research and Development Expense (Quarterly): 1.972M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 1.972M |
September 30, 2023 | 83.66M |
June 30, 2023 | 3.954M |
March 31, 2023 | 3.562M |
December 31, 2022 | 4.093M |
September 30, 2022 | 8.31M |
June 30, 2022 | 3.983M |
March 31, 2022 | 3.403M |
December 31, 2021 | 4.992M |
September 30, 2021 | 4.487M |
June 30, 2021 | 4.45M |
March 31, 2021 | 3.007M |
December 31, 2020 | 4.175M |
September 30, 2020 | 3.749M |
June 30, 2020 | 4.35M |
March 31, 2020 | 4.223M |
December 31, 2019 | 6.309M |
September 30, 2019 | 4.597M |
June 30, 2019 | 4.629M |
March 31, 2019 | 3.308M |
December 31, 2018 | 8.417M |
September 30, 2018 | 4.538M |
June 30, 2018 | 3.705M |
March 31, 2018 | 3.259M |
December 31, 2017 | 3.405M |
Date | Value |
---|---|
September 30, 2017 | 2.705M |
June 30, 2017 | 2.452M |
March 31, 2017 | 2.814M |
December 31, 2016 | 2.821M |
September 30, 2016 | 2.494M |
June 30, 2016 | 2.509M |
March 31, 2016 | 3.546M |
December 31, 2015 | 3.832M |
September 30, 2015 | 3.043M |
June 30, 2015 | 2.578M |
March 31, 2015 | 2.350M |
December 31, 2014 | 2.384M |
September 30, 2014 | 2.886M |
June 30, 2014 | 2.099M |
March 31, 2014 | 2.749M |
December 31, 2013 | 2.068M |
September 30, 2013 | 2.804M |
June 30, 2013 | 2.132M |
March 31, 2013 | 1.092M |
December 31, 2012 | 0.7447M |
September 30, 2012 | 0.6548M |
June 30, 2012 | 0.5327M |
March 31, 2012 | 0.7273M |
December 31, 2011 | 0.9602M |
September 30, 2011 | 0.6141M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.972M
Minimum
Dec 2023
83.66M
Maximum
Sep 2023
8.521M
Average
4.223M
Median
Mar 2020
Research and Development Expense (Quarterly) Benchmarks
Pfizer Inc | 2.815B |
Sarepta Therapeutics Inc | 195.52M |
PTC Therapeutics Inc | 121.35M |
Corcept Therapeutics Inc | 54.71M |
Cytokinetics Inc | -- |